Prenatal Diagnosis publishes Sequenom CMM’s MaterniT21 PLUS LDT clinical study

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication from the large Women & Infants multi-center clinical study on the Sequenom Center for Molecular Medicine’s (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) has been published online in the peer-reviewed journal, Prenatal Diagnosis. Continue reading

Sequenom Announces Coverage Agreement With Coventry Health Care For Sequenom Center For Molecular Medicine's …

SAN DIEGO, May 9, 2012 /PRNewswire/ — Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has signed an agreement with U.S. health insurance provider Coventry Health Care National Network to provide coverage for the Sequenom Center for Molecular Medicine’s (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT). Continue reading